Veracyte Announces Data for Pulmonology Portfolio to be Presented at American Thoracic Society 2021 International Conference - Seite 2
First Author:
Joshua Babiarz, Ph.D., Veracyte
Title:
Envisia Genomic Classifier Demonstrates Consistent Performance Across Gender, Age Group, and Smoking Status. Abstract #A1839
First Author:
Luca Richeldi, M.D., Ph.D., Università Cattolica del Sacro Cuore, Rome, Italy
Title:
Envisia Genomic Classifier Helps Improve Multidisciplinary Diagnoses of Complex Interstitial Lung Diseases, Abstract #A1877
First Author:
Lisa H. Lancaster, M.D., Vanderbilt University Medical Center
Title:
Cryobiopsy and Genomic Classifier (Envisia) in the Diagnosis of Usual Interstitial Pneumonia, Abstract #A4236
First Author:
R. Ronaghi, M.D., University of California, Los Angeles
Title:
Role of the Envisia Genomic Classifier in Establishing a Diagnosis of Idiopathic Pulmonary Fibrosis, Abstract #1837
First Author:
M. Abdalla, M.D., Pulmonary and Critical Care Medicine, Medical College of Wisconsin
Title:
Bridging the Envisia Genomic Classifier to the nCounter Platform: A Proof-of-Concept Study, Abstract #A4352
First Author:
Huimin Jiang, Ph.D., Veracyte
About Veracyte
Lesen Sie auch
Veracyte (Nasdaq: VCYT) is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping and renal cancer tests are in development. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).